Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis, Protocol for RIAlta Phase 2b/c Trial

  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Ghimire, Samiksha|||0000-0002-6028-1460
  • Sturkenboom, Marieke G. G.|||0000-0002-3420-0591
  • Alffenaar, Jan-Willem C.|||0000-0001-6703-0288
  • Tavares, Margarida|||0000-0003-4518-2197
  • Aguirre, Sarita|||0000-0002-8752-2762
  • Battaglia, Arturo
  • Molinas, Gladys
  • Tórtola Fernández, María Teresa|||0000-0002-9188-298X
  • Akkerman, Onno|||0000-0001-5638-9260
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Magis-Escurra, Cecile|||0000-0001-8424-9425
Previous clinical trials for drug-susceptible tuberculosis (DS-TB) have shown that first-line treatment with doses of rifampicin up to 40 mg/kg are safe and increase the early treatment response for young adults with pulmonary tuberculosis. This may lead to a shorter treatment duration for those persons with TB and a good baseline prognosis, or increased treatment success for vulnerable subgroups (age.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Safety, Efficacy and Pharmacokinetics of daily optimised doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis

  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Aguiar, Ana|||0000-0001-7841-7410
  • Nara, Eva
  • Medina, Angelica
  • Molinas, Gladys
  • Tavares, Margarida|||0000-0003-4518-2197
  • Tórtola Fernández, María Teresa|||0000-0002-9188-298X
  • Ghimire, Samiksha|||0000-0002-6028-1460
  • Alfenaar, Jan-Willem C.
  • Sturkenboom, Marieke G. G.|||0000-0002-3420-0591
  • Magis-Escurra, Cecile|||0000-0001-8424-9425
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Barros, Henrique
  • Duarte, Raquel
Background: Higher than standard doses of rifampicin could improve the treatment outcome of drug-susceptible tuberculosis without compromising the safety of patients. Methods: We performed a systematic review of prospective clinical studies including adults with pulmonary and extrapulmonary TB receiving rifampicin doses above 10mg/kg/day. We extracted the data on overall adverse events (AE), hepatic AE, sputum culture conversion (SCC) at week 8, recurrence, mortality, and pharmacokinetics. We performed a Bayesian network meta-analysis (NMA) using a random-effects model. Results: In 19 studies, 2033 out of 3654 participants received rifampicin doses higher than 10mg/kg/day. The NMA showed an increased risk of overall and hepatic AE for the 40mg/kg/day dose (RR 4.8, 95% CrI 1.1; 25, and 15.00, 95% CrI 1.1; 58.0, respectively), but no other doses, including 50mg/kg/day showed such an increase. Increasing doses improved sputum culture conversion at week 8 (RR 1.3, 95% CrI 1.1; 1.7 for SCC with 35mg/kg/day). Conclusion: Optimal doses of rifampicin may be between 25 and 35mg/kg/day, but should be tailored at the individual or, at least, at the population level.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial

  • Espinosa Pereiro, Juan
  • Ghimire, Samiksha
  • Sturkenboom, Marieke G.G.
  • Alffenaar, Jan-Willem
  • Tavares, Margarida
  • Aguirre García, Sarita Katerinne
  • Tórtola Fernández, Mª Teresa
  • Sánchez Montalvá, Adrián
Rifampicin; Tuberculosis; Vulnerable population, Rifampicina; Tuberculosis; Población vulnerable, Rifampicina; Tuberculosi; Població vulnerable, Previous clinical trials for drug-susceptible tuberculosis (DS-TB) have shown that first-line treatment with doses of rifampicin up to 40 mg/kg are safe and increase the early treatment response for young adults with pulmonary tuberculosis. This may lead to a shorter treatment duration for those persons with TB and a good baseline prognosis, or increased treatment success for vulnerable subgroups (age > 60, diabetes, malnutrition, HIV, hepatitis B or hepatitis C coinfection, TB meningitis, stable chronic liver diseases). Here, we describe the design of a phase 2b/c clinical study under the hypothesis that rifampicin at 35 mg/kg is as safe for these vulnerable groups as for the participants included in previous clinical trials. RIAlta is an interventional, open-label, multicenter, prospective clinical study with matched historical controls comparing the standard DS-TB treatment (isoniazid, pyrazinamide, and ethambutol) with rifampicin at 35 mg/kg (HR35ZE group) vs. rifampicin at 10 mg/kg (historical HR10ZE group). The primary outcome is the incidence of grade ≥ 3 Adverse Events or Severe Adverse Events. A total of 134 participants will be prospectively included, and compared with historical matched controls with at least a 1:1 proportion. This will provide a power of 80% to detect non-inferiority with a margin of 8%. This study will provide important information for subgroups of patients that are more vulnerable to TB bad outcomes and/or treatment toxicity. Despite limitations such as non-randomized design and the use of historical controls, the results of this trial may inform the design of future more inclusive clinical trials, and improve the management of tuberculosis in subgroups of patients for whom scientific evidence is still scarce. Trial registration: EudraCT 2020-003146-36, NCT04768231., This study is part of the European South American TB Research Collaborative Network (EUSAT-RCS), a project that has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 823890. A.S.M. is supported by a Juan Rodés (JR18/00022) postdoctoral fellowship from ISCIII.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial

  • Espinosa Pereiro, Juan
  • Ghimire, Samiksha
  • Sturkenboom, Marieke G.G.
  • Alffenaar, Jan-Willem
  • Tavares, Margarida
  • Aguirre García, Sarita Katerinne
  • Tórtola Fernández, Mª Teresa
  • Sánchez Montalvá, Adrián
Rifampicin; Tuberculosis; Vulnerable population, Rifampicina; Tuberculosis; Población vulnerable, Rifampicina; Tuberculosi; Població vulnerable, Previous clinical trials for drug-susceptible tuberculosis (DS-TB) have shown that first-line treatment with doses of rifampicin up to 40 mg/kg are safe and increase the early treatment response for young adults with pulmonary tuberculosis. This may lead to a shorter treatment duration for those persons with TB and a good baseline prognosis, or increased treatment success for vulnerable subgroups (age > 60, diabetes, malnutrition, HIV, hepatitis B or hepatitis C coinfection, TB meningitis, stable chronic liver diseases). Here, we describe the design of a phase 2b/c clinical study under the hypothesis that rifampicin at 35 mg/kg is as safe for these vulnerable groups as for the participants included in previous clinical trials. RIAlta is an interventional, open-label, multicenter, prospective clinical study with matched historical controls comparing the standard DS-TB treatment (isoniazid, pyrazinamide, and ethambutol) with rifampicin at 35 mg/kg (HR35ZE group) vs. rifampicin at 10 mg/kg (historical HR10ZE group). The primary outcome is the incidence of grade ≥ 3 Adverse Events or Severe Adverse Events. A total of 134 participants will be prospectively included, and compared with historical matched controls with at least a 1:1 proportion. This will provide a power of 80% to detect non-inferiority with a margin of 8%. This study will provide important information for subgroups of patients that are more vulnerable to TB bad outcomes and/or treatment toxicity. Despite limitations such as non-randomized design and the use of historical controls, the results of this trial may inform the design of future more inclusive clinical trials, and improve the management of tuberculosis in subgroups of patients for whom scientific evidence is still scarce. Trial registration: EudraCT 2020-003146-36, NCT04768231., This study is part of the European South American TB Research Collaborative Network (EUSAT-RCS), a project that has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 823890. A.S.M. is supported by a Juan Rodés (JR18/00022) postdoctoral fellowship from ISCIII.